SEC Comment Letter 0000000000-23-005788 to Sunshine Biopharma Inc. (SBFM)
Sunshine Biopharma Inc.
Date: June 1, 2023 · CIK: 0001402328 · Accession: 0000000000-23-005788
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272197
Letter
United States securities and exchange commission logo June 1, 2023 Dr. Steve N. Slilaty Chief Executive Officer Sunshine Biopharma, Inc 6500 Trans-Canada Highway 4th Floor Pointe-Claire, Quebec, Canada H9R 0A5 Re:Sunshine Biopharma, Inc Registration Statement on Form S-3 Filed May 25, 2023 File No. 333-272197 Dear Dr. Steve N. Slilaty: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeff Cahlon, Esq.
Show Raw Text
United States securities and exchange commission logo
June 1, 2023
Dr. Steve N. Slilaty
Chief Executive Officer
Sunshine Biopharma, Inc
6500 Trans-Canada Highway
4th Floor
Pointe-Claire, Quebec, Canada H9R 0A5
Re:Sunshine Biopharma, Inc
Registration Statement on Form S-3
Filed May 25, 2023
File No. 333-272197
Dear Dr. Steve N. Slilaty:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeff Cahlon, Esq.